SCHEMBL10271102

SCHEMBL10271102

CNc1ccc(-c2nc3ccccc3o2)cc1N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.57
RAB9A P51151 9/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
ATM Q13315 1/20 0.57
KDM4E B2RXH2 10/20 0.53
ALDH1A1 P00352 9/20 0.53
HPGD P15428 8/20 0.53
SMN1; SMN2 Q16637 7/20 0.53
MAPT P10636 5/20 0.53
TP53 P04637 3/20 0.53
NFKB1 P19838 3/20 0.53
NFKB2 Q00653 3/20 0.53
RELA Q04206 3/20 0.53
GAA P10253 3/20 0.53
STAT1 P42224 2/20 0.53
LMNA P02545 1/20 0.53
GFER P55789 1/20 0.53
HSD17B10 Q99714 5/20 0.50
HCRTR1 O43613 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2687836 0.85 NPC1 (0.54) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2687468 0.85 NPC1 (0.54) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2688443 0.85 NPC1 (0.54) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2686640 0.85 NPC1 (0.50) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2688292 0.83 NPC1 (0.51) NPC1RAB9AMEN1KMT2AATM
SCHEMBL1065877 0.82 NPC1 (0.68) NPC1RAB9AMEN1KMT2AATM
SCHEMBL12997040 0.82 NPC1 (0.52) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2688693 0.82 NPC1 (0.52) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2688673 0.81 TLR8 (0.50) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2493904 0.81 NPC1 (0.64) NPC1RAB9AMEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
EP-2436683-B1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL CO (JP) 2014-05-14 EP disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed
CN-102428080-A Therapeutic or prophylactic agent for diseases in which neurotrophic factor activity participates SUMITOMO CHEMICAL CO 2012-04-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 NPC1 525/4885RAB9A 2914/4885MEN1 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.